CRISPR Therapeutics AG (:CRSP) currently has an A verage Broker Rating of 1.73. This number is based on the 11 sell-side firms polled by Zacks. The ABR rank within the industry stands at 12. Analysts on a consensus basis are expecting that the stock will reach $87.77 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.

Investors might be taking a closer look into the crystal ball to try and decipher what is in store for the second half of the year in the stock market. While cautious optimism may be the prevailing sentiment, many investors will be looking to take the portfolio to the next level. With markets still riding high, the big question is whether the momentum will push stocks higher or if the bears start to take over. There may still be a few undervalued stocks with much more upside potential ready to make big moves. Finding these stocks may involve doing a little more homework. Investors may be looking to take advantage of any little sell-off that might provide some bargain buying opportunities.      

CRISPR Therapeutics AG (:CRSP) closed the last session at $86.4 and sees an average of 1211447 shares trade hands in each session. The 52-week low of the stock stands at $33.68 while the current level stands at 85.56% of the 52-week High-Low range. Looking further out we can see that the stock has moved 66.15% over the past 12 weeks and 41.86% year to date.

Research analysts are predicting that CRISPR Therapeutics AG (:CRSP) will report earnings of $-1.18 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Most recently CRISPR Therapeutics AG (:CRSP) posted quarterly earnings of $-1.3 which compared to the sell-side estimates of -0.92. The stock’s 12-month trailing earnings per share stands at $0.46. Shares have moved $17.57 over the past month and more recently, $-7.64 over the past week heading into the earnings announcement. There are 8 analyst projections that were taken into consideration from respected brokerage firms.

8 analysts rate CRISPR Therapeutics AG a Buy or Strong Buy, which is 72.73% of all the analyst ratings.

As the next earnings season comes into focus, investors will be keeping watch on the performance of companies that they own. A company that continually exceeds earnings projections is most likely on the right track. On the other end of the spectrum, a company that frequently misses earnings projections might provide some insight to the fact that something isn’t right. Although it is important to keep track of earnings estimates and results, it shouldn’t be the only thing that the investor is looking at regarding the stock. Just because a company misses or beats expectations for one quarter may not mean anything super special. Tracking performance over a longer period of time can help paint the bigger picture of what is going on with the company. Sharp investors often have the ability to look deeper into the numbers to see the actual causes of an earnings hit or miss. Of course estimates are just that, estimates, and some analysts may be more accurate than others. 

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.



Source link